Trapped platelets activated in ischemia initiate ventricular fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 6, Issue 5, 2013, Pages 995-1001

  Dhanjal, Tarvinder S ^a   Medina, Rodolfo A ^b   Leem, Jinwoo ^a   Clark, James E ^a   Southworth, Richard ^b   Curtis, Michael J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiarrhythmia agent; Antiarrhythmic drug development; Arrhythmias; Blood platelets; Cardiac; Death; Myocardial ischemia; Sudden

Indexed keywords

BUFFER; CLOPIDOGREL; INDIUM 111; INDOMETACIN; THROMBOXANE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ELECTROCARDIOGRAPHY; EX VIVO STUDY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART PERFUSION; HEART VENTRICLE FIBRILLATION; HEPARINIZATION; IN VIVO STUDY; ISCHEMIA; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; THROMBOCYTE; ANIMAL; ANTIARRHYTHMIC DRUG DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SUDDEN CARDIAC DEATH; WISTAR RAT; COMPLICATION; VENTRICULAR FIBRILLATION;

ANTIARRHYTHMIA AGENT; ANTIARRHYTHMIC DRUG DEVELOPMENT; ARRHYTHMIAS, CARDIAC; BLOOD PLATELETS; DEATH, SUDDEN, CARDIAC; MYOCARDIAL ISCHEMIA;

ANIMALS; AUTORADIOGRAPHY; BLOOD PLATELETS; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, WISTAR; VENTRICULAR FIBRILLATION;

EID: 84891392264     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.000591     Document Type: Article

References (37)

1. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K, Jui J. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51:213-228.
2. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol. 2001;12:369-381.
3. John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG. Ventricular arrhythmias and sudden cardiac death. Lancet. 2012;380:1520-1529.
4. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP; The SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Survival with Oral d-Sotalol. Lancet. 1996;348:7-12.
5. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
6. Camm AJ, Julian D, Janse G, Munoz A, Schwartz P, Simon P, Frangin G; EMIAT Investigators. The European Myocardial Infarct Amiodarone Trial (EMIAT). Am J Cardiol. 1993;72:95F-98F.
7. Clements-Jewery H, Andrag E, Curtis MJ. Druggable targets for sudden cardiac death prevention: lessons from the past and strategies for the future. Curr Opin Pharmacol. 2009;9:146-153.
8. Curtis MJ, Pugsley MK, Walker MJ. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res. 1993;27:703-719.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;8607:349-360.
10. Askari AT, Lincoff AM. GUSTO V: combination drug treatment of acute myocardial infarction. Global use of strategies to open occluded coronary arteries. Cleve Clin J Med. 2002;69:554-560.
11. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288:2130-2135.
12. Koltai M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res. 1991;25:391-397.
13. Stahl GL, Terashita Z, Lefer AM. Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia. J Pharmacol Exp Ther. 1988;244:898-904.
14. Auchampach JA, Maruyama M, Cavero I, Gross GJ. The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther. 1991;259:961-967.
15. Ahn YK, Cho JG, Park WS, Kim NH, Kim JW, Kim SH, Cho JH, Park JH, Jeong MH, Park JC, Kang JC. The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats. Jpn Heart J. 1999;40:79-86.
16. Fagbemi SO. The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias in anaesthetized rats. Eur J Pharmacol. 1984;97:283-287.
17. Moschos CB, Haider B, De La Cruz C, Lyons MM, Regan TJ. Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion. Circ. 1978;57:681-684.
18. De Jong J S S G, Dekker L R C. Platelets and cardiac arrhythmia. Frontiers Physiol. 2010;1:166.
19. Curtis MJ, Hearse DJ. Reperfusion-induced arrhythmias are critically dependent upon occluded zone size: relevance to the mechanism of arrhythmogenesis. J Mol Cell Cardiol. 1989;21:625-637.
20. Curtis MJ. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res. 1998;39:194-215.
21. Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, Roden DM, Camm AJ, Walker MJ. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013;139:213-248.
22. Dhanjal TS, Ross EA, Auger JM, McCarty OJ, Hughes CE, Senis YA, Buckley CD, Watson SP. Minimal regulation of platelet activity by PECAM-1. Platelets. 2007;18:56-67.
23. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103:2096-2104.
24. Flores NA, Botchway AN, Stavrou BM, Sheridan DJ. Cardiac electrophysiological effects of platelet-derived substances. Exp Physiol. 1999;84:253-274.
25. Coker SJ, Parratt JR, Ledingham IM, Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature. 1981;291:323-324.
26. Leo R, Praticò D, Iuliano L, Pulcinelli FM, Ghiselli A, Pignatelli P, Colavita AR, Fitz Gerald GA, Violi F. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation. 1997;95:885-891.
27. Clements-Jewery H, Hearse DJ, Curtis MJ. Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. Br J Pharmacol. 2002;135:807-815.
28. Ridley PD, Yacoub MH, Curtis MJ. A modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis. Cardiovasc Res. 1992;26:309-315.
29. Baker KE, Wood LM, Whittaker M, Curtis MJ. Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation? Br J Pharmacol. 2006;149:269-276.
30. Johnston KM, MacLeod BA, Walker MJ. Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size. Br J Pharmacol. 1983;78:29-37.
31. Auchampach JA, Pieper GM, Cavero I, Gross GJ. Effect of the plateletactivating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998;93:361-371.
32. Wainwright CL, Parratt JR, Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur Heart J. 1989;10:235-243.
33. Chakrabarty S, Fluck DS, Flores NA, Sheridan DJ. Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol. 1992;107:705-709.
34. Clements-Jewery H, Andrag E, Hearse DJ, Curtis MJ. Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats. Br J Pharmacol. 2009;156:444-453.
35. Yong AS, Pennings GJ, Chang M, Hamzah A, Chung T, Qi M, Brieger D, Behnia M, Krilis SA, Ng MK, Lowe HC, Kritharides L. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood. 2011;117:11-20.
36. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36:699-705.
37. De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule-II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989;61:43-49.